Krown S E, Pinsky C M, Hirshaut Y, Hansen J A, Oettgen H F
Isr J Med Sci. 1978 Oct;14(10):1026-38.
Eighteen patients with advanced cancer were given subcutaneous injections of pooled dialyzable transfer factor (TFd) from normal donors for periods of from 9 days to 6.5 months. Minor tumor regression was observed in only two patients, an effect of no therapeutic significance. However, treatment with TFd was associated with at least a temporary increase in delayed hypersensitivity reactions in 12 of 17 patients tested, including four patients who became responsive to 2,4-dinitrochlorobenzene. In general, in vitro tests of immune function were not changed after treatment with TFd except for levels of C1q, and/or C3, which were increased in 6 of 10 patients tested. We conclude that TFd may augment delayed hypersensitivity in patients with advanced cancer, and that its effects are, at least in part, immunologically nonsepcific.
18例晚期癌症患者接受了来自正常供体的混合可透析转移因子（TFd）皮下注射，注射时间为9天至6.5个月。仅在2例患者中观察到轻微肿瘤消退，这一效果无治疗意义。然而，在17例接受检测的患者中，有12例使用TFd治疗后至少出现迟发型超敏反应暂时增强，其中4例患者对2,4-二硝基氯苯产生反应。总体而言，除了C1q和/或C3水平外，TFd治疗后免疫功能的体外测试无变化，在10例接受检测的患者中有6例C1q和/或C3水平升高。我们得出结论，TFd可能增强晚期癌症患者的迟发型超敏反应，并且其作用至少部分是免疫非特异性的。
